Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16657253 | 0.91 | MAPT (0.33) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL16657251 | 0.90 | GAA (0.31) | MAPT | |
| SCHEMBL15093213 | 0.90 | PSIP1 (0.32) | — | |
| SCHEMBL1699706 | 0.85 | HSD17B10 (0.35) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL10271716 | 0.85 | HSD17B10 (0.35) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL15099754 | 0.84 | HTT (0.38) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL1699726 | 0.83 | MAPT (0.35) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL15165315 | 0.83 | MAPT (0.35) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL15093279 | 0.83 | SMN1; SMN2 (0.34) | MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL15099650 | 0.83 | SMN1; SMN2 (0.34) | MAPTHTTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | MAPT 671/4885HTT 1606/4885SMN1; SMN2 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.